An enzyme in microsomal fraction of kidney that inactivates bradykinin☆,☆☆
References (6)
- et al.
J. Biol. Chem.
(1951) Advances in Pharmacology
(1966)- et al.
Cited by (108)
Angiotensin-converting enzyme
2023, Metalloenzymes: From Bench to BedsidePreoperative angiotensin converting enzyme inhibitor usage in patients with chronic subdural hematoma: Associations with initial presentation and clinical outcome
2016, Journal of Clinical NeuroscienceCitation Excerpt :Fujisawa et al. showed that the activation of the kallikrein-kinin system in cSDH patients causes increasing vascular permeability with subsequent hematoma enlargement due to blood extravasation from neomembranes [13]. The rationale to investigate angiotensin converting enzyme (ACE) inhibitors in the setting of cSDH is that ACE inhibitors are known to cause elevated levels of bradykinin [14,15], the end-product of the kallikrein-kinin system that has been linked to enlargement of cSDH hematoma volume. The existing literature on the association between ACE inhibitors and cSDH is scarce and results have been mixed [16,17].
Antihypertensive effect of novel angiotensin I converting enzyme inhibitory peptide from chum salmon (Oncorhynchus keta) skin in spontaneously hypertensive rats
2014, Journal of Functional FoodsCitation Excerpt :Its treatment is effective in reducing the risk of cardiovascular disease including arteriosclerosis, stroke and myocardial infarction (Sheih, Fang, & Wu, 2009). Angiotensin converting enzyme (ACE) catalyzes the production of angiotensin II (Ang II) from angiotensin I (Ng & Vane, 1968), and degrade bradykinin (Skeggs, Marsh, Khan, & Shumway, 1954), which result in the elevation of blood pressure (Erdos & Yang, 1967; Yang & Erdos, 1967; Yang, Erdos, & Levin, 1971). The conversions of both of these substrates are domain-dependent as the N-terminal domain of somatic ACE cleaves the terminal dipeptide of bradykinin and the C-terminal domain produces Ang II (Igic, Nakajima, Yeh, Sorrells, & Erdos, 1973).
Plasminogen activator inhibitor-1 and angiotensin converting enzyme gene polymorphisms in Turkish asthmatic children
2013, Allergologia et ImmunopathologiaCitation Excerpt :Another candidate gene proposed to be involved in the pathogenesis of asthma is angiotensin converting enzyme (ACE) gene. Angiotensin converting enzyme plays an essential role in the metabolism of angiotensin II (AT II) and inactivates bradykinins and tachykinins which are bronchoconstrictors and also mediators of inflammation in asthma.12 Angiotensin II is also involved in the pathogenesis of asthma by interaction with airway smooth muscle.
Evaluation of angiotensin converting enzyme gene polymorphism and susceptibility to bronchial asthma among Egyptians
2012, Allergologia et ImmunopathologiaCitation Excerpt :Angiotensin converting enzyme (ACE) gene is one of these genes. ACE is expressed at high levels in the lungs, and exhibits an anti-inflammatory effect through catabolising bradykinins and tachykinins, which induce smooth muscle airway constriction, bronchial edema, mucus hyper-secretion, and neurogenic inflammation.5 On the other hand, ACE converts angiotensin I into the vasoactive angiotensin II, which through causing proliferation and contractility of airway smooth muscles, can contribute to excessive airway obstruction.6
Combination inhibition of the renin-angiotensin system: Is more better
2011, Kidney International
- ☆
Supported in part by Grant HE 08764 from the National Institutes of Health, U.S.P.H.S.
- ☆☆
Presented in part in the III International Pharmacological Congress, Sao Paulo 1966.